What is LIRADS (Liver Imaging Reporting and Data System)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is LI-RADS?

LI-RADS (Liver Imaging Reporting and Data System) is a comprehensive standardized system developed by the American College of Radiology to standardize the acquisition, interpretation, and reporting of CT, MRI, and contrast-enhanced ultrasound examinations in patients at risk for hepatocellular carcinoma (HCC). 1

Core Purpose and Design

LI-RADS provides a structured framework to categorize liver observations based on their probability of being HCC, non-HCC malignancy, or benign lesions. 1 The system was created through collaboration among radiologists, hepatologists, pathologists, and surgeons to address the full spectrum of lesions and pseudolesions encountered in at-risk populations. 1, 2

Categorization System

LI-RADS assigns observations into specific categories that reflect diagnostic certainty: 1, 3

  • LR-1: Definitely benign
  • LR-2: Probably benign
  • LR-3: Intermediate probability of malignancy
  • LR-4: Probably HCC
  • LR-5: Definitely HCC
  • LR-M: Probably or definitely malignant, but not HCC-specific (e.g., intrahepatic cholangiocarcinoma)
  • LR-TIV: Tumor in vein
  • LR-NC: Non-categorizable due to image degradation or technical issues

Major Imaging Features

The system uses specific major features to categorize observations: 1, 4

  • Arterial phase hyperenhancement (APHE): Nonrim arterial enhancement greater than surrounding liver
  • Washout appearance: Temporal reduction in enhancement relative to liver in portal venous or delayed phases
  • Enhancing capsule: Smooth, uniform rim enhancement in portal venous or delayed phases
  • Size: Measured in millimeters
  • Threshold growth: Specific growth criteria over time

The diagnostic algorithm combines these features with lesion size to assign categories, with LR-5 requiring nonrim APHE plus either washout or enhancing capsule (depending on size). 1

Applicable Imaging Modalities

LI-RADS encompasses four distinct algorithms: 2

  • Ultrasound for HCC surveillance
  • CT and MRI for HCC diagnosis and tumor staging
  • Contrast-enhanced ultrasound (CEUS) for HCC diagnosis
  • CT/MRI for treatment response assessment

LI-RADS is the only major guideline system that permits definitive HCC diagnosis using CEUS as the initial imaging modality. 1 CEUS LI-RADS uses modified criteria, with LR-5 requiring APHE followed by late (>60 seconds) and mild washout. 1

Target Population

The system applies specifically to patients at high risk for HCC, including those with: 1, 2

  • Cirrhosis (any etiology)
  • Chronic hepatitis B infection
  • Current or prior HCC

Clinical Integration and Validation

LI-RADS demonstrates high accuracy in stratifying HCC and malignancy probabilities, with systematic reviews confirming its diagnostic performance. 1 A 2023 meta-analysis showed clear stratification of HCC percentages across LI-RADS categories on both CT and MRI. 1

The 2025 EASL guidelines and 2018 AASLD guidelines both incorporate LI-RADS into their diagnostic algorithms, reflecting its acceptance as a standard approach. 1 The system has been integrated with the Organ Procurement Transplantation Network/United Network for Organ Sharing criteria. 2

Ancillary Features

Beyond major features, LI-RADS incorporates ancillary features that radiologists may use at their discretion to upgrade categories (up to but not beyond LR-4) or apply additional modifiers. 1, 5 These features help refine categorization when major features alone are insufficient.

Standardized Reporting

LI-RADS provides specific templates for reporting observations, either in continuous paragraph format or structured format with keywords. 6 This standardization facilitates multidisciplinary communication and clinical decision-making. [6, @17@, @18@]

Important Limitations

CEUS LI-RADS has specific constraints: it has fewer ancillary features than CT/MRI, permits characterization of only a limited number of targeted observations per examination (preferably those visible on precontrast ultrasound), and is not suitable for staging. 1

Arterial phase iso- or hypoenhancing observations cannot be categorized as LR-5 (definite HCC), though they may qualify as LR-4 (probable HCC) with appropriate combinations of other major features. 1

Evolution and Updates

The system has undergone iterative refinement since 2011 based on scientific evidence, expert opinion, and user feedback, with the most recent version being LI-RADS v2018. 1, 2 The goal is progressive worldwide adoption culminating in a single unified international system. 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Introduction to the Liver Imaging Reporting and Data System for Hepatocellular Carcinoma.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2019

Research

Cirrhotic liver: What's that nodule? The LI-RADS approach.

Journal of magnetic resonance imaging : JMRI, 2016

Research

LI-RADS ancillary features on contrast-enhanced ultrasonography.

Ultrasonography (Seoul, Korea), 2020

Research

How to Use LI-RADS to Report Liver CT and MRI Observations.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.